Drug Profile
Benzgalantamine - AlphaCognition
Alternative Names: Alpha 1062; ALPHA-1062 Intranasal; ALPHA-1062IN; Galantamine benzoate - AlphaCognition; Galantamine pro-drug - AlphaCognition; GLN-1062; Memogain; Pro-galantamine - AlphaCognitionLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Galantos Pharma
- Developer AlphaCognition
- Class Alkaloids; Antidementias; Benzazepines; Benzoates; Nootropics; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Nicotinic receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Alzheimer's disease
- Preclinical Traumatic brain injuries
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for clinical-Phase-Unknown development in Alzheimer's-disease in Unknown (Sublingual, Tablet)
- 22 Feb 2024 Alpha Cognition files for patent protection with USPTO for composition of matter in USA
- 12 Feb 2024 Pharmacokinetics and adverse events data from clinical trial in Alzheimer's disease released by AlphaCognition